Multiple pulmonary nodules
Conditions
Interventions
Anxiety group and non combined anxiety group (Part I of the study):None
Research group (Part II of the study):
Perioperative optimized management + auricular vagus nerve stimulation
Control group (Part II of the study):Perioperative routine management + auricular vagus nerve sham stimulation
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: The first part of the study included the following criteria: (1) age 18-70 years; (2) Patients who have been diagnosed as multiple pulmonary nodules by chest surgeons according to CT results and have clear indications for surgery, and have been included in the elective surgery plan; (3)ASA classification I-III; (4) Voluntary participation in this study and signing of informed consent; (5) Have the cognitive ability to complete the anxiety assessment scale and perioperative follow-up. Inclusion criteria in the second part of the study: (1) Age 18-70 years; (2) Patients who have been diagnosed as multiple pulmonary nodules by chest surgeons according to CT results and whose surgical indications are clear and have been included in the elective surgery plan; (3)ASA classification I-III; (4) Voluntary participation in this study and signing of informed consent; (5) Have the cognitive ability to complete the anxiety assessment scale and perioperative follow-up.
Exclusion criteria
Exclusion criteria: Exclusion criteria in the first part of the study: (1) Previous diagnosis of severe mental illness (schizophrenia, bipolar disorder, etc.); (2) Combined with active infection, advanced malignant tumor, autoimmune disease or severe organ dysfunction; (3) Use of glucocorticoids, immunosuppressants or psychotropic drugs in the past month; (4) pregnant or lactating women; (5) Past history of severe complications of difficult airway and anesthesia. Exclusion criteria in the second part of the study: (1) Previous diagnosis of severe mental illness (schizophrenia, bipolar disorder, etc.); (2) Combined with active infection, advanced malignant tumor, autoimmune disease or severe organ dysfunction; (3) Use of glucocorticoids, immunosuppressants or psychotropic drugs in the past month; (4) pregnant or lactating women; (5) Past history of difficult airway, serious complications of anesthesia or contraindications to taVNS (such as ear infection and pacemaker implantation); (6) Refusing or failing to cooperate with the intervention of perioperative taVNS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuroendocrine index cortisol;Neuroendocrine index norepinephrine;Neuroendocrine index adrenaline;Immune cell subsets Th1;Cytokine detection TNF-a;Immune cell subsets Th2;Immune cell subsets Treg;Cytokine detection IL-6;Cytokine detection IL-10;Hamilton anxiety scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain score;Incidence of postoperative nausea and vomiting;Incidence of postoperative delirium;Hospitalized time ;Dosage of anesthetic drugs; | — |
Countries
China
Contacts
Public ContactHuaqin Liu
The Fourth Hospital of Hebei Medical University
Outcome results
None listed